H. Lundbeck A/S

143 articles about H. Lundbeck A/S

• H. Lundbeck A/S Increases Its Share Capital By 115,722 Shares (0.0590% Of Outstanding Shares) As A Result Of Employee Warrant Exercise

  5/21/2014

• Announcement Of Transactions With Shares And Linked Securities In H. Lundbeck A/S Made By Executives And Their Closely Associated Persons And Legal Entities

  5/7/2014

• H. Lundbeck A/S Receives Grant From The The Michael J. Fox Foundation For Biological Markers Identification In Parkinson’s Disease

  5/5/2014

• H. Lundbeck A/S And Otsuka Pharmaceutical Co., Ltd. Release: Caregivers Of People With Schizophrenia Need Support, Not Stigma

  5/2/2014

• FDA Accepts For Review Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S’s Supplemental New Drug Application To Expand Abilify Maintena® (Aripiprazole) Labelling

  4/30/2014

• H. Lundbeck A/S Release: Treatment With Once-Monthly Abilify Maintena® (Aripiprazole) Significantly Reduces Hospitalisation Rates For Patients With Schizophrenia Compared With Daily Oral Antipsychotics

  4/7/2014

• H. Lundbeck A/S To Enter Into A Partnership With World-Renowned Research Institute

  3/31/2014

• New Incentive Plan For Executive Management In H. Lundbeck A/S

  3/27/2014

• H. Lundbeck A/S Held Its Annual General Meeting On 26 March 2014 At The Company's Registered Office

  3/27/2014

• H. Lundbeck A/S And Otsuka Pharmaceutical Co., Ltd. Initiate European Launch Of Abilify Maintena® (Aripiprazole), A Once-Monthly Formulation For The Treatment Of Schizophrenia

  3/17/2014

• H. Lundbeck A/S Release: Notice Of Annual General meeting

  3/4/2014

• The Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S Alliance Announces Once-Monthly (Pr)ABILIFY MAINTENA(™) (ARIPIPRAZOLE For Prolonged Release Injectable Suspension)1 Now Approved In Canada For The Maintenance Treatment Of Schizophrenia In Stabilized

  2/13/2014

• Otsuka Pharmaceutical Co., Ltd. And H. Lundbeck A/S To Present New Data On Brexpiprazole In Major Depression (MDD) At European Congress Of Psychiatry (EPA)

  1/24/2014

• H. Lundbeck A/S's Brintellix® (Vortioxetine) For The Treatment Of Major Depressive Disorder In Adults Is Now Available In U.S. Pharmacies

  1/21/2014

• EU Approves Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S's Once-Monthly Abilify Maintena® For Schizophrenia

  11/21/2013

• H. Lundbeck A/S Receives Positive Opinion for Approval of Brintellix (Vortioxetine) in the European Union

  10/25/2013

• H. Lundbeck A/S Increases Its Share Capital by 11,204 Shares (0.006% of Outstanding Shares) as a Result of Employee Warrant Exercise

  8/20/2013

• Announcement of Transactions With Shares and Linked Securities in H. Lundbeck A/S Made by Executives and Their Closely Associated Persons and Legal Entities

  8/16/2013

• H. Lundbeck A/S Says It Will Restructure, Cut Jobs

  6/21/2013

• H. Lundbeck A/S Intends to Appeal the Decision From the European Commission

  6/19/2013